• A trial vaccine is showing promise for treating aggressive forms of several cancers, including, ovarian, bowel, prostate and gastroesophageal cancers. The experimental shot teaches the immune system to recognize cells that are multiplying out of control due to a mutation along the HER2 gene. In about 25 percent of breast cancers, HER2 mutations make the tumors grow more aggressively, and dramatically increase the risks that the disease will come back, even after remission. The new immunotherapy, developed by the National Institutes of Health, has not yet been tested in breast cancers, but it may be able to counteract the rogue gene. So far, it has stopped growth in 54 percent of HER2 tumors in small trial and even eradicated one woman’s ovarian cancer for 18 months over the course of the newly-published clinical trial.
Photo credit: medicalnewstoday.com